#$LLY also guiding material price declines but guidance handily topped estimates. Orforglipron is their oral GLP-1. *ELI LILLY SEES 2026 REV. $80B TO $83B, EST. $77.71B *ELI LILLY SEES GLOBAL PRICING DECLINE IN LOW- TO MID-TEENS *LILLY EXPECTS ORFORGLIPRON U.S. LAUNCH IN 2Q, PENDING FDA NOD

RE: https://bsky.app/profile/did:plc:pnx2fjuannbdpy3337ggthpp/post/3mdxslend3s2a